These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26701387)

  • 21. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.
    Loaëc N; Attanasio E; Villiers B; Durieu E; Tahtouh T; Cam M; Davis RA; Alencar A; Roué M; Bourguet-Kondracki ML; Proksch P; Limanton E; Guiheneuf S; Carreaux F; Bazureau JP; Klautau M; Meijer L
    Mar Drugs; 2017 Oct; 15(10):. PubMed ID: 29039762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
    Tahtouh T; Elkins JM; Filippakopoulos P; Soundararajan M; Burgy G; Durieu E; Cochet C; Schmid RS; Lo DC; Delhommel F; Oberholzer AE; Pearl LH; Carreaux F; Bazureau JP; Knapp S; Meijer L
    J Med Chem; 2012 Nov; 55(21):9312-30. PubMed ID: 22998443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temperature does matter-an additional dimension in kinase inhibitor development.
    Strauch M; Heyd F
    FEBS J; 2021 May; 288(10):3148-3153. PubMed ID: 32946682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effect of CLK SR Kinases on HIV-1 gene expression: potential novel targets for therapy.
    Wong R; Balachandran A; Mao AY; Dobson W; Gray-Owen S; Cochrane A
    Retrovirology; 2011 Jun; 8():47. PubMed ID: 21682887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
    Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
    EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors.
    Saldivia M; Fang E; Ma X; Myburgh E; Carnielli JBT; Bower-Lepts C; Brown E; Ritchie R; Lakshminarayana SB; Chen YL; Patra D; Ornelas E; Koh HXY; Williams SL; Supek F; Paape D; McCulloch R; Kaiser M; Barrett MP; Jiricek J; Diagana TT; Mottram JC; Rao SPS
    Nat Microbiol; 2020 Oct; 5(10):1207-1216. PubMed ID: 32661312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.
    ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective inhibition of the kinase DYRK1A by targeting its folding process.
    Kii I; Sumida Y; Goto T; Sonamoto R; Okuno Y; Yoshida S; Kato-Sumida T; Koike Y; Abe M; Nonaka Y; Ikura T; Ito N; Shibuya H; Hosoya T; Hagiwara M
    Nat Commun; 2016 Apr; 7():11391. PubMed ID: 27102360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computer-aided identification of novel protein targets of bisphenol A.
    Montes-Grajales D; Olivero-Verbel J
    Toxicol Lett; 2013 Oct; 222(3):312-20. PubMed ID: 23973438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. cDNA cloning and characterization of rat Clk3, a LAMMER kinase predominately expressed in testis.
    Becker W; Kentrup H; Heukelbach J; Joost HG
    Biochim Biophys Acta; 1996 Jun; 1312(1):63-7. PubMed ID: 8679717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
    Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
    J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
    ElHady AK; Abdel-Halim M; Abadi AH; Engel M
    J Med Chem; 2017 Jul; 60(13):5377-5391. PubMed ID: 28561591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).
    Rosenthal AS; Tanega C; Shen M; Mott BT; Bougie JM; Nguyen DT; Misteli T; Auld DS; Maloney DJ; Thomas CJ
    Bioorg Med Chem Lett; 2011 May; 21(10):3152-8. PubMed ID: 21450467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
    Murai A; Ebara S; Sasaki S; Ohashi T; Miyazaki T; Nomura T; Araki S
    PLoS One; 2020; 15(10):e0240718. PubMed ID: 33064779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
    MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution.
    Colwill K; Pawson T; Andrews B; Prasad J; Manley JL; Bell JC; Duncan PI
    EMBO J; 1996 Jan; 15(2):265-75. PubMed ID: 8617202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization.
    Mohanty S; Oruganty K; Kwon A; Byrne DP; Ferries S; Ruan Z; Hanold LE; Katiyar S; Kennedy EJ; Eyers PA; Kannan N
    PLoS Genet; 2016 Feb; 12(2):e1005885. PubMed ID: 26925779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases.
    Verkhivker GM
    Bioinformatics; 2006 Aug; 22(15):1846-54. PubMed ID: 16720585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The highly conserved LAMMER/CLK2 protein kinases prevent germ cell overproliferation in Drosophila.
    Zhao S; Chen D; Geng Q; Wang Z
    Dev Biol; 2013 Apr; 376(2):163-70. PubMed ID: 23376537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.